Remdesivir: On average 11 instead of 15 days with Covid-19
With great effort, an effective drug against Covid-19 is sought. Remdesivir is great hope. A current study, which also uses placebos, clarifies why this is the case.
The drug remdesivir from the US biotech company Gilead apparently works in many COVID 19 patients. A study showed that recovery time decreased by four days or 31 percent compared to placebo patients, according to the National Institutes of Health (NIH) in Washington. The death rate is also somewhat lower. However, a final evaluation of the study was not yet available.
The investigation, which started on February 21, 2020, collected 1063 patients from ten countries. The participants received the antiviral remdesivir or a placebo. Neither the patients nor the doctors knew who was getting which product. The time to recovery in patients with remdesivir averaged 11 days. In contrast, the patients with placebo had 15 days. Patients were classified as having recovered if they were discharged from the hospital with sufficient medical stability. During the study, doctors followed the clinical status of the patients on an eight-point scale that ranged from complete recovery to death.
“Our results underscore the need to identify Covid-19 cases and begin antiviral treatment before the lung disease progresses to the point where artificial ventilation is required,” wrote the NIH researchers. In particular, they consider a combination of remdesivir with other treatments to be promising.
To date, there is no vaccine or medication against coronavirus-induced lung disease Covid-19. Gilead recently received US approval for the use of remdesivir in emergencies after the drug company provided data that showed the drug could shorten the course of the disease in patients.